Virometix AG

Company founded: September 2009

Virometix develops a new generation of vaccines using its Synthetic Virus-Like Particle (SVLP) technology, which enables the creation of a novel type of synthetic nanoparticles.

Virometix develops a new generation of vaccines using its Synthetic Virus-Like Particle (SVLP) technology, which enables the creation of a novel type of synthetic nanoparticles. Similarly to real viruses, SVLPs can generate a strong and long-lasting immune response. However, unlike real viruses, SVLPs are made entirely by chemical synthesis with associated advantages in stability, safety, production and quality control, and are completely modular. This enables the design of tailored vaccines for the prevention and treatment of a broad range of infectious and chronic human diseases. Virometix is developing several vaccines including one against streptococcal diseases.

Virometix AG

Arin Ghasparian

Wagistrasse 14
8952 Zürich

http://www.virometix.com

Contact

Sharing

PARTNERS